| 生物活性 |
ODZ10117 is a STAT3 and NLRP3 inhibitor with an IC50 of 7.5 μM against the human STAT3 SH2 domain; it binds the STAT3 SH2 domain to inhibit tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity, and binds NLRP3 to disrupt its interaction with NEK7, inhibit inflammasome formation, and block caspase-1 and IL-1β cleavage; it also reduces MSU (MS-E13881)-induced IL-1β release, decreases LPS (MS-X54539)-induced sepsis mortality, and induces apoptosis, exhibiting anti-inflammatory effects, and can be used for research on MSU-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease. |
体外研究 (In Vitro) |
ODZ10117 (Compound 86) (5-40 μM;6 小时) 在孵育 6 小时后,浓度高达 40 μM 时对小鼠骨髓来源巨噬细胞无显著细胞毒性。 ODZ10117 (5-20 μM;1 小时预处理) 可剂量依赖性地抑制经 ATP、尼日利亚菌素、二氧化硅晶体或咪喹莫特处理的 LPS 预刺激小鼠骨髓来源巨噬细胞中 NLRP3 炎症小体介导的 IL-1β 释放和细胞焦亡,在 20 μM 时抑制作用达到最强。 ODZ10117 (5-20 μM;1 小时预处理) 可通过抑制 caspase-1、IL-1β 和 GSDMD 的切割,在经 LPS 预处理的小鼠骨髓来源巨噬细胞中抑制 NLRP3 炎性小体的活化,且不会改变炎性小体核心组分的表达水平。 ODZ10117 (5-20 μM;1 小时预处理) 不会抑制经 LPS 预处理的小鼠骨髓来源巨噬细胞中 AIM2 或 NLRC4 炎症小体的激活,表明其对 NLRP3 炎症小体具有特异性。 ODZ10117 (5-20 μM;1 小时预处理) 可剂量依赖性地抑制 LPS 预刺激的小鼠骨髓来源巨噬细胞中 NLRP3 炎症小体介导的 ASC 转位、寡聚化及斑点形成,且不影响 AIM2 或 NLRC4 炎症小体激活过程中的 ASC 动力学。 ODZ10117 (20 μM) 可在过表达 NLRP3 与 NEK7 的 HEK293T 细胞中抑制二者的相互作用。 ODZ10117 (300-900 μM;30 min incubation with lysates) 可直接与 LPS 预处理的 J774A.1 细胞裂解物中的 NLRP3 和 STAT3 结合,这一点可通过其对链霉蛋白酶降解的剂量依赖性保护作用得到证实,且该化合物不与 NEK7 或 caspase-1 结合。 ODZ10117 通过多种稳定相互作用结合于 NLRP3 NACHT 结构域的 ADP 结合口袋,结合能为 -7.7 kcal/mol。 ODZ10117 可紧密结合至 STAT3 SH2 结构域的磷酸酪氨酸结合口袋,其 Glide 对接得分为 −6.17 kcal/mol,结合亲和力高于已知 STAT3 抑制剂 S3I-201 (MS-O77981) 和 STA-21 (MS-O80539)。 ODZ10117 (40 μM;24 小时) 可抑制多种组成型激活 STAT3 的人类癌细胞系 (包括 HDLM-2、MDA-MB-231、HepG2 和 U87MG) 中 STAT3 的酪氨酸磷酸化。 ODZ10117 (40 μM;24 小时) 可抑制 IL-6 诱导的人癌细胞系 (包括 RPMI8226、MCF-7 和 U251MG) 中 STAT3 的酪氨酸磷酸化。 ODZ10117 (40 μM;24 小时) 可抑制转染的 MDA-MB-231 乳腺癌细胞中 STAT3 的同源二聚化及酪氨酸磷酸化。 ODZ10117 (40 μM;24 小时) 可通过激活 caspase-3、切割 PARP 并下调抗凋亡蛋白 Bcl-2、Bcl-xL、Mcl-1 和 survivin,诱导 MDA-MB-231 乳腺癌细胞发生凋亡。 ODZ10117 (40 μM;24 小时) 可抑制 MDA-MB-231 乳腺癌细胞中酪氨酸磷酸化 STAT3 的核转位。 ODZ10117 (2.5-40 μM;24 小时) 可抑制 MDA-MB-231/STAT3-Luc 乳腺癌细胞中 STAT3 的转录活性,孵育 24 小时后的 IC50 为 7.5 μM。 ODZ10117 (40 μM;0.5-12 小时) 可在处理后 2 小时开始抑制 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞中 STAT3 的酪氨酸磷酸化。 ODZ10117 (10-40 μM;9 小时) 以浓度依赖的方式抑制 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞中 STAT3 的酪氨酸磷酸化,孵育 9 小时后在 ≥20 μM 浓度下可产生显著抑制作用。 ODZ10117 (40 μM;16 小时) 可在 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞中特异性抑制 STAT3 的酪氨酸磷酸化,而不影响其他 STAT 家族蛋白、JAK 激酶或上游信号调节因子 Akt、Src 及 ERK1/2。 ODZ10117 (10-100 μM;24 小时) 以浓度依赖的方式降低 MDA-MB-231、MDA-MB-468、ZR-75-1 和 4T1 乳腺癌细胞的活力。 ODZ10117 (40 μM;24 小时) 可增加 MDA-MB-231 乳腺癌细胞的凋亡性细胞死亡,Annexin V 阳性细胞数量增加 5 倍、PI 阳性细胞数量增加 3 倍可证明这一点。 ODZ10117 (40 μM;24 小时) 可下调 MDA-MB-231 乳腺癌细胞中 STAT3 依赖性抗凋亡基因 Bcl-2、Bcl-xL、Mcl-1 和 Survivin 的 mRNA 表达。 ODZ10117 (40 μM;24 小时) 可在伤口愈合实验中降低 MDA-MB-231 乳腺癌细胞的迁移能力。 ODZ10117 可强效且选择性地抑制乳腺癌细胞中 STAT3 的转录活性,其 IC50 为 7.5 μM。 ODZ10117 通过直接阻断 STAT3 SH2 结构域、抑制同源二聚化与转录活性、诱导细胞凋亡并降低迁移及侵袭能力,对 MDA-MB-231 乳腺癌细胞发挥抗癌作用。 ODZ10117 (10 μM;12 小时预处理) 可通过减轻氧化应激诱导的细胞损伤,提高经 H2O2 处理的人神经母细胞瘤 SH-SY5Y 细胞的存活率。 ODZ10117 (10 μM;12 小时预处理) 可抑制 H2O2 诱导的人神经母细胞瘤 SH-SY5Y 细胞中 caspase 依赖性凋亡。 ODZ10117 (10 μM;12 小时预处理) 可抑制人神经母细胞瘤 SH-SY5Y 细胞中 STAT3 的磷酸化,并诱导 ERK 和 CREB 的短暂磷酸化,其作用峰值出现在 1 小时。 ODZ10117 (10 μM;1-12 小时) 可上调人神经母细胞瘤 SH-SY5Y 细胞中记忆相关 IEGs 和 BDNF 的蛋白表达,且在 6 小时时即可检测到表达水平升高。 ODZ10117 (10 μM;3 小时) 诱导人神经母细胞瘤 SH-SY5Y 细胞中 CREB 磷酸化的过程依赖于 ERK 信号通路。 ODZ10117 (10 μM;3-6 小时) 可上调人神经母细胞瘤 SH-SY5Y 细胞中与记忆相关的 IEGs 的 mRNA 表达,在 3 小时时效应达到峰值。 ODZ10117 (10 μM;12 小时) 诱导人神经母细胞瘤 SH-SY5Y 细胞中记忆相关 IEG 和 BDNF 蛋白上调的作用依赖于 ERK 信号通路。 ODZ10117 (10 μM;12 小时预处理) 在人神经母细胞瘤 SH-SY5Y 细胞中缓解 H2O2 诱导的氧化应激和 caspase 依赖性凋亡的能力依赖于 ERK 信号通路。
Cell Cytotoxicity Assay
| Cell Line: |
mouse bone marrow-derived macrophages (BMDMs) |
| Concentration: |
5 μM; 10 μM; 20 μM; 40 μM |
| Incubation Time: |
6 h |
| Result: |
Showed no significant cytotoxicity on BMDMs at concentrations up to 40 μM, with cell viability remaining near 100% across all tested concentrations. |
Western Blot Analysis
| Cell Line: |
LPS-primed mouse bone marrow-derived macrophages (BMDMs) |
| Concentration: |
5 μM; 10 μM; 20 μM |
| Incubation Time: |
1 h pretreatment |
| Result: |
Dose-dependently inhibited the cleavage of pro-caspase-1 to active caspase-1 (p20), pro-IL-1β to active IL-1β (p17), and full-length GSDMD to N-terminal GSDMD (N-GSDMD) in cell supernatants and lysates. Had no effect on the steady-state protein levels of NLRP3, ASC, pro-caspase-1, pro-IL-1β, or full-length GSDMD in cell lysates. |
Immunofluorescence
| Cell Line: |
LPS-primed mouse bone marrow-derived macrophages (BMDMs) |
| Concentration: |
5 μM; 10 μM; 20 μM |
| Incubation Time: |
1 h pretreatment |
| Result: |
Dose-dependently suppressed ASC translocation to Triton X-100 insoluble fractions, ASC oligomerization, and ASC speck formation in BMDMs treated with NLRP3 triggers (ATP, nigericin, silica crystals). Reduced ASC speck formation by ~50% for ATP and nigericin triggers at 20 μM. Had no effect on ASC translocation or speck formation in BMDMs treated with AIM2 or NLRC4 triggers. |
Western Blot Analysis
| Cell Line: |
HDLM-2, L540, K562, KCL22, LAMA84, DU145, MDA-MB-231, MDA-MB-468, SKOV3, PANC-1, A549, NCI-H460, HCT116, SW620, MKN-45, A431, A375, SK-MEL-146, HepG2, Huh7, A172, U87MG, U373MG, SH-SY5Y |
| Concentration: |
40 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced the level of tyrosine-phosphorylated STAT3 in all tested constitutively STAT3-activated human cancer cell lines, without altering total STAT3 levels. |
Western Blot Analysis
| Cell Line: |
RPMI8226, U266, U937, HL-60, HeLa, MCF-7, U251MG |
| Concentration: |
40 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced the level of tyrosine-phosphorylated STAT3 induced by IL-6 stimulation in all tested human cancer cell lines, without altering total STAT3 levels. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: |
24 h |
| Result: |
Decreased the level of tyrosine-phosphorylated STAT3 without altering total STAT3 levels, and significantly reduced STAT3 homodimerization compared to vehicle-treated cells.\nIncreased the levels of cleaved PARP and cleaved caspase-3, and reduced the protein levels of anti-apoptotic genes Bcl-2, Bcl-xL, Mcl-1, and Survivin compared to vehicle-treated cells. |
Immunofluorescence
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced the nuclear accumulation of tyrosine-phosphorylated STAT3 compared to vehicle-treated cells, where phosphorylated STAT3 was prominently localized in the nucleus. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: |
0.5 h; 1 h; 2 h; 4 h; 6 h; 9 h; 12 h |
| Result: |
Reduced tyrosine-phosphorylated STAT3 levels after 2 h of incubation, with the inhibitory effect sustained through 12 h of treatment, without altering total STAT3 levels. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
10 μM; 20 μM; 30 μM; 40 μM |
| Incubation Time: |
9 h |
| Result: |
Reduced tyrosine-phosphorylated STAT3 levels in a concentration-dependent manner, with significant inhibition observed at concentrations ≥20 μM, without altering total STAT3 levels. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: |
16 h |
| Result: |
Inhibited tyrosine phosphorylation of STAT3, but did not significantly affect phosphorylation levels of STAT1, STAT5, JAK1, JAK2, JAK3, Akt, Src, or ERK1/2, nor did it alter total levels of any of these proteins. |
Cell Viability Assay
| Cell Line: |
MDA-MB-231, MDA-MB-468, ZR-75-1, and 4T1 breast cancer cells |
| Concentration: |
10 μM; 20 μM; 40 μM; 60 μM; 80 μM; 100 μM |
| Incubation Time: |
24 h |
| Result: |
Decreased cell viability in a concentration-dependent manner across all tested breast cancer cell lines. At 100 μM, cell survival was reduced to 30-50% of vehicle-treated controls. |
Apoptosis Analysis
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: |
24 h |
| Result: |
Increased the population of PI-positive dead cells from 7.86% to 26.7% and Annexin V-positive apoptotic cells from 3.13% to 15.3% compared to vehicle-treated cells. |
Real Time qPCR
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced the mRNA levels of Bcl-2, Bcl-xL, Mcl-1, and Survivin to 20-40% of vehicle-treated control levels. |
Cell Migration Assay
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
40 μM |
| Incubation Time: | ...(内容过长已截断)
体内研究 (In Vivo) |
ODZ10117 (Compound 86) (5-20 mg/kg;腹腔注射;单次给药) 可剂量依赖性地降低尿酸钠 (MSU) 诱导的腹膜炎小鼠的 IL-1β 释放量,在 10 和 20 mg/kg 剂量下可观察到显著的抑制作用。 ODZ10117 (5-20 mg/kg;腹腔注射;LPS 给药前 12 h 和 2 h 分两次给药) 可剂量依赖性地降低 LPS 诱导脓毒症小鼠的 IL-1β 释放并提高其存活率,在 10 和 20 mg/kg 剂量下观察到显著疗效。 ODZ10117 (1-10 mg/kg;腹腔注射;每周 5 次;持续 23 天) 以剂量依赖方式抑制 BALB/c 裸鼠的原位乳腺肿瘤生长,其中 10 mg/kg 剂量的肿瘤减重效果优于 1 mg/kg 剂量。 ODZ10117 (10 mg/kg;瘤内注射;每 2 天 1 次;持续 2 周) 可抑制 BALB/c 裸鼠的皮下乳腺肿瘤生长,并调控肿瘤组织中 STAT3 依赖的凋亡及转移标志物。 ODZ10117 (1-10 mg/kg;腹腔注射;每周 5 次;持续 3 周) 可抑制 BALB/c 小鼠同源乳腺癌模型中的原发肿瘤生长、减少肺转移并延长生存期,且 10 mg/kg 剂量的疗效优于 1 mg/kg 剂量。 ODZ10117 (10 mg/kg;瘤内注射) 可显著抑制携带 MDA-MB-231 乳腺癌异种移植物的 BALB/c 小鼠的肿瘤生长与肺转移。
| Animal Model: |
C57BL/6 (female, 6-8 weeks old, intraperitoneal injection of MSU crystals at 50 mg/kg) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Suppressed MSU-induced IL-1β release in a dose-dependent manner. Achieved statistically significant reductions in IL-1β levels at 10 mg/kg and 20 mg/kg (p < 0.01) compared to the MSU-only group. |
| Animal Model: |
C57BL/6 (female, 6-8 weeks old, intraperitoneal injection of LPS at 20 mg/kg) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
i.p.; two doses (12 h and 2 h prior to LPS) |
| Result: |
Suppressed LPS-induced IL-1β release in a dose-dependent manner. Achieved statistically significant reductions in IL-1β levels at 10 mg/kg and 20 mg/kg (p < 0.05) compared to the LPS-only group. Improved survival rate: maintained 60% survival through 80 hours at 20 mg/kg, compared to 0% survival for the LPS-only group by 36 hours, with a statistically significant difference (p < 0.05). |
| Animal Model: |
BALB/c nude (6-week-old female, orthotopic xenograft via MDA-MB-231 cell injection into right fourth mammary fat pad) |
| Dosage: |
1 mg/kg; 10 mg/kg |
| Administration: |
i.p.; 5 times per week; 23 days |
| Result: |
Reduced final tumor weight to ~1.8 g (1 mg/kg dose) compared to vehicle control ~2.4 g. Suppressed tumor volume growth over 22 days (1 mg/kg dose). Reduced final tumor weight to ~1.4 g (10 mg/kg dose). Suppressed tumor volume growth to a greater degree than the 1 mg/kg dose (10 mg/kg dose). Did not affect mouse body weight (both doses). |
| Animal Model: |
BALB/c nude (6-week-old female, subcutaneous xenograft via MDA-MB-231 cell injection into neck) |
| Dosage: |
10 mg/kg |
| Administration: |
intratumoral injection; every 2 days; 2 weeks |
| Result: |
Significantly suppressed relative tumor volume growth over 14 days, with final relative volume ~2 compared to vehicle control ~5. Reduced tumor cell population in treated tumors. Decreased levels of pY705-STAT3, Bcl-xL, and pro-MMP-2 in treated tumors. Increased levels of active caspase-3 in treated tumors. |
| Animal Model: |
BALB/c (6-week-old female, syngeneic xenograft via 4T1-Luc cell injection into right fourth mammary fat pad, spontaneous lung metastasis) |
| Dosage: |
1 mg/kg; 10 mg/kg |
| Administration: |
i.p.; 5 times per week; 3 weeks |
| Result: |
Reduced primary tumor volume at 21 days (1 mg/kg dose). Increased median mouse survival from 12 days to 20 days (1 mg/kg dose). Reduced visible lung metastatic nodules to ~22 compared to vehicle control ~30 (1 mg/kg dose). Reduced primary tumor volume to a greater degree than the 1 mg/kg dose (10 mg/kg dose). Increased median survival to 21 days (10 mg/kg dose). Reduced visible lung metastatic nodules to ~17 (10 mg/kg dose). Did not affect mouse body weight (both doses). |
| Animal Model: |
BALB/c |
| Dosage: |
10 mg/kg |
| Administration: |
intratumoral injection |
| Result: |
Significantly reduced tumor growth and lung metastasis. |
|
| 分子量 |
362.42 |
| 分子式 |
C10H5Cl5N2O2 |
| CAS No. |
1632152-27-2 |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|